Yang Shaoyu, Wu Liming, Li Xin, Huang Jie, Zhong Jianbo, Chen Xueqin
Department of Medical Oncology, Hangzhou First People's Hospital, Nanjing Medical University, Hangzhou, Zhejiang 310006, P.R. China.
Department of Dermatology, Hangzhou First People's Hospital, Nanjing Medical University, Hangzhou, Zhejiang 310006, P.R. China.
Mol Clin Oncol. 2018 Mar;8(3):457-459. doi: 10.3892/mco.2018.1553. Epub 2018 Jan 11.
Crizotinib is an oral small-molecule inhibitor of anaplastic lymphoma kinase (ALK) tyrosine-kinase that has been approved for treating patients with advanced echinoderm microtubule associated protein like 4-ALK rearranged non-small-cell lung cancer (NSCLC). Toxic epidermal necrolysis (TEN) is a rare adverse event associated with crizotinib. The present study reported a case of a 75-year-old Chinese male patient with advanced NSCLC with ALK fusion, who developed TEN after 56 days of crizotinib treatment and demised due to this dermatological adverse event. The occurrence of severe cutaneous necrolysis that predominantly involves the skin and mucous membranes during crizotinib treatment should alert clinicians to be aware of TEN and take prompt actions.
克唑替尼是一种口服的间变性淋巴瘤激酶（ALK）酪氨酸激酶小分子抑制剂，已被批准用于治疗晚期棘皮动物微管相关蛋白样4-ALK重排的非小细胞肺癌（NSCLC）患者。中毒性表皮坏死松解症（TEN）是与克唑替尼相关的一种罕见不良事件。本研究报告了一例75岁的中国男性晚期ALK融合NSCLC患者，在接受克唑替尼治疗56天后发生TEN，并因这一皮肤不良事件死亡。在克唑替尼治疗期间出现主要累及皮肤和黏膜的严重皮肤坏死溶解情况，应提醒临床医生注意TEN并迅速采取行动。
